Which Country Is Zejula (Niraparib) Cheapest In? — 2026 Guide

Why does the price differ so much between countries?

Zejula (niraparib) is GSK's poly (ADP-ribose) polymerase (PARP) inhibitor, approved as maintenance therapy for both first-line and recurrent ovarian, fallopian tube or primary peritoneal cancer following response to platinum-based chemotherapy. It is supplied as 100 mg capsules and, in a newer formulation, as 100 mg tablets, taken once daily by mouth, allowing patients to continue maintenance treatment at home rather than attending an infusion unit. Because it is self-administered and dispensed through the retail and specialty-pharmacy channel rather than hospital procurement, Zejula's published price is set, updated and disclosed through community reimbursement mechanisms rather than hospital tender processes, and that channel difference is central to why its list price varies by country.

Within the PARP-inhibitor class, Zejula competes for guideline positioning against other agents used in ovarian cancer maintenance, and the number of reimbursed alternatives in a given country materially affects how a payer negotiates any single product's published price. Because Zejula is evaluated separately for its first-line and recurrent maintenance indications, and sometimes restricted by biomarker status such as homologous recombination deficiency in some health systems, the same capsule or tablet can carry different negotiated prices depending on which approved use and patient subgroup is being reimbursed in a particular market.

In Türkiye, TİTCK applies external reference pricing to oral oncology products just as it does to biologics: the published price tracks the lowest ex-factory price found across a defined basket of EU reference countries, converted using the fixed "pharmaceutical euro" (Dönemsel Avro Değeri) rather than the live market rate, as published on the TİTCK price list and periodically updated via the Resmî Gazete. Germany evaluates Zejula under its AMNOG early-benefit-assessment framework, with free pricing for the first months followed by a negotiated price backdated to month seven. NICE in England applies its cost-per-QALY threshold, raised from the long-standing £20,000–£30,000 range to £25,000–£35,000, announced 1 December 2025 and effective from April 2026 (see NICE).

The United States has no equivalent government reference mechanism for an oral oncology drug like Zejula: list prices are set largely freely by the manufacturer and then negotiated privately with pharmacy benefit managers and insurers, so the headline list price and what any individual patient pays can diverge sharply, a pattern documented across countries in the RAND 2024 international price comparison. Because Zejula moves through retail and specialty pharmacy rather than hospital tenders, co-pay assistance programmes and formulary tiering are the main factors separating published price from what most patients actually pay. For more on the structural reasons behind Türkiye's published prices, see our explainer on why medicines cost less in Türkiye.

How is the price set in each country?

The table below compares pricing systems, not prices. Each country publishes — or does not publish — its own official list, and that published list is the only figure worth relying on. Follow the link in the last column and read the current entry yourself.

How can I obtain a medicine legally from a lower-price market?

There is a lawful route in most countries, and it starts in the same place everywhere: a valid prescription in your own name, issued by the physician treating you. What differs is the import permit. The procedures below are stated only where they could be verified at the national authority.

United Arab Emirates. MOHAP operates a permit to import medicines for personal use through its Electronic Drug Establishment service. The permit is free and is issued within 3 working days. You log in with a MOHAP account or UAE Pass.

Saudi Arabia. Applications run through the SFDA Controlled Drugs System at cds.sfda.gov.sa, under a guideline published on 14 August 2025. Read the current SFDA regulations page before you travel — the requirements are revised periodically.

Qatar. For non-controlled medicines there is no pre-approval: you may carry up to a 60-day supply through the Green Channel, in the original packaging, with a copy of the prescription and a signed, stamped letter from your doctor. For controlled medicines you need advance approval and must use the Red Channel; supporting documents must be no older than 6 months and in Arabic or English.

Kuwait and Azerbaijan. Confirm the current procedure directly with the national authority before shipping or travelling — Kuwait Ministry of Health and Azerbaijan Tariff Council. We do not publish a step list for these two countries because the procedure could not be verified at source.

1. United Arab Emirates — obtain a prescription in the applicant's own name, issued within the last 3 months.
2. Obtain a medical report from the treating facility, authenticated by the health authority and issued within the last year.
3. Prepare an Emirates ID or passport copy for the applicant.
4. Log in to the MOHAP service with a MOHAP account or UAE Pass and submit the personal-import application.
5. Keep the quantity within the limit: no more than a 1-month supply for controlled medicines, and no more than a 3-month supply for non-controlled medicines.
6. Wait for the decision — the service is free and normally issued within 3 working days.
7. Contact MOHAP on 800 111 11 or at import.export@mohap.gov.ae if the application stalls.

What is named patient supply?

Named patient supply is the international concept behind almost every lawful cross-border medicine route. The clearest codified example is the United Kingdom's MHRA Guidance Note 14, built on Regulation 167 of the Human Medicines Regulations 2012.

Four conditions define it: the order must be unsolicited; the product must be specified by the prescriber; the prescriber must be directly responsible for the patient; and there must be a genuine special clinical need that no authorised product meets.

The honesty point matters here: the European Court has held that "financial considerations cannot, in themselves" establish a special clinical need. A lower price in another country is not, by itself, a lawful basis for a named-patient import. The lawful bases are clinical.

Is the Zejula I'm being offered genuine?

No falsified batches of this product have been recorded in WHO's alert series to date. That absence does not prove that any individual pack is authentic — it only means there is no documented incident to cite, and readers should verify each pack on its own merits rather than relying on the absence of a public alert, per the WHO medical product alert list.

Because Zejula is a capsule or tablet dispensed in a carton with a blister strip or bottle rather than a single-dose vial, verification depends heavily on checking the outer packaging and the printed batch and expiry information before the pack is opened, since a loose dose separated from its carton loses most of its traceable information.

• Check that the outer carton is sealed and shows no signs of having been re-glued, re-taped or opened and re-closed before dispensing.
• Confirm the capsule or tablet's colour, imprint and size match the GSK product information leaflet for the 100 mg strength and formulation dispensed.
• Match the batch number and expiry date printed on the carton against the numbers printed on the blister foil or bottle label inside — they must be identical.
• Scan the carton's GS1 DataMatrix and confirm it decodes to AI 01 (GTIN), AI 21 (serial number), AI 17 (expiry) and AI 10 (batch).
• If sourced in Türkiye, verify the karekod is registered on the national İlaç Takip Sistemi (İTS) track-and-trace system at its.saglik.gov.tr before dispensing.
• Store the capsules or tablets at room temperature, protected from heat and moisture — Zejula does not require refrigeration, and any pack offered from a source claiming it must be kept refrigerated should raise suspicion.
• Never accept loose capsules or tablets sold without their original carton and blister or bottle: once separated from that packaging, a dose cannot be verified against any batch or expiry record. Review our guide to checking that a medicine is genuine and our WHO falsified medicine alerts tracker before dispensing.

Frequently asked questions

Sources

• Resmî Gazete — Beşeri Tıbbi Ürünlerin Fiyatlandırılmasına Dair Karar No. 11031 — retrieved: 2026-07-28
• TİTCK — published medicine price list — retrieved: 2026-07-28
• MOHAP (UAE) — import medicine for personal use — retrieved: 2026-07-28
• SFDA (Saudi Arabia) — regulations — retrieved: 2026-07-28
• SFDA Controlled Drugs System — retrieved: 2026-07-28
• Qatar MOPH — drug prices — retrieved: 2026-07-28
• Kuwait Ministry of Health — retrieved: 2026-07-28
• Azerbaijan Tariff Council (Tarif Şurası) — retrieved: 2026-07-28
• NICE (United Kingdom) — retrieved: 2026-07-28
• G-BA (Germany) — AMNOG benefit assessment — retrieved: 2026-07-28
• RAND — International prescription drug price comparisons (published 1 Feb 2024) — retrieved: 2026-07-28
• Frontiers in Pharmacology — European hospital price transparency study (9 Mar 2026) — retrieved: 2026-07-28
• MHRA Guidance Note 14 — supply of unlicensed medicinal products — retrieved: 2026-07-28

Country availability pages for this medicine

Related pages

Targeted oral therapies

Related high-cost medicines